Cellumed Co

Cellumed Co Net Debt per Share

The Net Debt per Share of Cellumed Co (049180.KQ) as of Oct 28, 2026 is -46.23 KRW. In the previous year, Net Debt per Share was -3.59 KRW — a change of 1,188.62% (lower).

Net Debt per Share

-46.23KRW

YoY

1,188.62%

Last updated:

Net Debt per Share of Cellumed Co is 2024 -46.23 KRW. Net Debt per Share of Cellumed Co was 2023 -3.59 KRW. It decreases by 1,188.62% lower compared to the previous year.

The Cellumed Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
129.66 KRW
Jan 1, 2018
-0.47 KRW
Jan 1, 2019
-295.32 KRW
Jan 1, 2020
-354.76 KRW
Jan 1, 2021
-448.05 KRW
Jan 1, 2022
-79.67 KRW
Jan 1, 2023
-3.59 KRW
Jan 1, 2024
-46.23 KRW
The Cellumed Co Net Debt per Share history
YEARNet Debt per ShareYoY
-46.23KRW+1,188.62%
-3.59KRW-95.50%
-79.67KRW-82.22%
-448.05KRW+26.30%
-354.76KRW+20.13%
-295.32KRW+62,842.91%
-0.47KRW-100.36%
129.66KRW+97.87%
65.53KRW-75.98%
272.80KRW+273.96%
72.95KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Net Debt per Share of Cellumed Co is -46.23 KRW in 2024.

Net Debt per Share of Cellumed Co changed from -3.59 KRW to -46.23 KRW, representing a 1,188.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Cellumed Co

All Key Metrics — Cellumed Co